Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.
Arrowhead Pharmaceuticals's Enterprise Value for the quarter that ended in Mar. 2026 was $8,004.1 Mil.
Arrowhead Pharmaceuticals's EBIT for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $-159.8 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Arrowhead Pharmaceuticals EV-to-EBIT Related Terms
Arrowhead Pharmaceuticals EV-to-EBIT Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, Arrowhead Pharmaceuticals's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Arrowhead Pharmaceuticals EV-to-EBIT vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Arrowhead Pharmaceuticals's EV-to-EBIT distribution charts can be found below:
* The bar in red indicates where Arrowhead Pharmaceuticals's EV-to-EBIT falls into.
Arrowhead Pharmaceuticals's current Enterprise Value is $11,267.4 Mil.
Arrowhead Pharmaceuticals's EBIT for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $-159.8 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Arrowhead Pharmaceuticals (ARWR) has a EV-to-EBIT of -70.49 as of Jul. 29, 2026. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on Arrowhead Pharmaceuticals and its competitors. According to the industry distribution chart, Arrowhead Pharmaceuticals ranks #999999 out of 381 companies in the Biotechnology industry.
Is Arrowhead Pharmaceuticals' EV-to-EBIT too high?
Arrowhead Pharmaceuticals' current EV-to-EBIT is -70.49. Based on the distribution chart, Arrowhead Pharmaceuticals ranks #999999 out of 381 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Arrowhead Pharmaceuticals has a GF Score™ of 45/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Arrowhead Pharmaceuticals' EV-to-EBIT compare to AXSM and MDGL?
According to the Biotechnology industry distribution chart, Arrowhead Pharmaceuticals ranks #999999 out of 381 companies for EV-to-EBIT. This places Arrowhead Pharmaceuticals in the lower half of its industry. The industry median EV-to-EBIT is 12.81. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBIT for a Biotechnology company?
The median EV-to-EBIT among Biotechnology companies is 12.81, based on 381 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBIT significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBIT should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBIT mean?
A high EV-to-EBIT can signal that a stock is expensive relative to its fundamentals. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on Arrowhead Pharmaceuticals and its competitors. For the Biotechnology industry, the median EV-to-EBIT is 12.81 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Arrowhead Pharmaceuticals's current EV-to-EBIT is -70.49. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Arrowhead Pharmaceuticals stock overvalued right now?
Based on GuruFocus' analysis, Arrowhead Pharmaceuticals (ARWR) is currently considered Significantly Overvalued. The stock's GF Value™ is $49.35, compared to a current price of $85.74 — trading 73.7% above its estimated fair value. The current EV-to-EBIT is -70.49. Arrowhead Pharmaceuticals' overall GF Score™ is 45/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBIT calculated?
EV-to-EBIT is calculated from a company's financial statements. For Arrowhead Pharmaceuticals (ARWR), the current EV-to-EBIT is -70.49 as of Jul. 29, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Arrowhead Pharmaceuticals (ARWR) Overvalued in 2026?
Based on GuruFocus' analysis, Arrowhead Pharmaceuticals stock appears to be overvalued.
The current stock price of $85.74 is trading 73.7% above its estimated GF Value™ of $49.35.
GuruFocus considers Arrowhead Pharmaceuticals to be Significantly Overvalued.
Key valuation signals for ARWR:
EV-to-EBIT: -70.49
GF Value™: $49.35 vs. price of $85.74 (73.7% above fair value)
No single metric tells the full story. See the ARWR stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Arrowhead Pharmaceuticals Inc is a commercial-stage pharmaceutical company. It is focused on the development of medicines for diseases associated with genetic abnormalities or protein overproduction. The company develops potential RNAi therapies designed to inhibit the expression of genes known to trigger diseases. Its portfolio includes potential drugs targeting Cardiometabolic, Neuromuscular, Pulmonary, Liver, and other diseases. The company also develops RNAi products and clinical candidates designed to target different cell types within the body.
45GF Score
Get the complete analysis for ARWR
EV-to-EBIT is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ARWR has been successfully added to your 
